Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
HLA ; 102(2): 168-178, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37002719

ABSTRACT

JAK2 V617F-driven myeloproliferative neoplasms (MPNs) can escape immune surveillance through PD-L1 up-regulation and HLA class I pathway down-regulation. To complement these data we assessed the role of major histocompatibility complex class I-related genes (MICA and MICB) in JAK2 V617F+ MPNs. Using high resolution genotyping we identified two protective alleles, MICA*008:01 and MICA*016. MPN patients had significantly higher levels of soluble sMICA molecules. Peripheral blood JAK2 V617F+ granulocytes had higher surface expression of MICB but did not differ in the amount of MICA and MICB transcripts from normal granulocytes. MICA and MICB genes were significantly down-regulated in JAK2 V617F+ CD34+ cells from primary myelofibrosis patients in comparison to normal CD34+ hematopoietic stem cells. These data suggest minor but significant role of MICA and MICB genes in the pathogenesis of MPNs. It is also possible that MICA targeting approaches could be of clinical benefit for some of those patients.


Subject(s)
Myeloproliferative Disorders , Neoplasms , Humans , NK Cell Lectin-Like Receptor Subfamily K/genetics , Ligands , Alleles , Myeloproliferative Disorders/genetics , Myeloproliferative Disorders/metabolism , Neoplasms/genetics , Janus Kinase 2/genetics , Janus Kinase 2/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...